![18](https://www.srjnews.com/wp-content/uploads/2015/07/18.jpg)
Edwards Lifesciences Corp. (NYSE:EW) reported that it has decided to purchase CardiAQ Valve Technologies, a privately held company and developer of a transcatheter mitral valve replacement system. “Edwards’ primary strategy is to create valuable therapies that transform patient care. We believe the acquisition and integration of CardiAQ will advance our development of a transformational therapy for patients with mitral valve disease who aren’t well-served today,” said Michael A. Mussallem, Edwards’ chairman and CEO. “While still early in the development of this therapy, the progress of the team of employees and clinicians working on our FORTIS mitral replacement system has reinforced our confidence in a catheter-based approach. We believe the experiences and technologies of FORTIS and CardiAQ are complementary and that this combination will enable important advancements for patients.” On the other consideration, Edwards Lifesciences Corp. (NYSE:EW) begun last trade with a price of $147.50 and throughout the trading session climbed at $148.45. The day-trade ended with a gain of 1.44% to close at $147.16.
M&T Bank Corporation (NYSE:MTB) reported that it has released the results of its “company-run” mid-cycle 2015 Dodd-Frank Act Stress Test. This in order is available on M&T’s website and under Regulatory Disclosures. M&T is a financial holding company headquartered in Buffalo, New York. M&T’s principal banking subsidiary, M&T Bank, operates banking offices in New York, Pennsylvania, Maryland, Virginia, West Virginia, Delaware and the District of Columbia. Trust-related services are provided by M&T’s Wilmington Trust-affiliated companies and by M&T Bank. Shares of M&T Bank Corporation (NYSE:MTB) opened at $126.01 with 132.97 million outstanding shares and hit to its highest price of $126.48 during the day and finally closed at $126.21 by scoring 1.63%. In the whole session, it traded on volume of 603966 shares, which turned higher than its average volume.
An agricultural biotechnology company, Ceres, Inc. (NASDAQ:CERE) reported that its results for the three months ended May 31, 2015 and provided an update on its business as well as product development pipeline. The firm released that it has signed a collaboration and license agreement with a leading agricultural producer to introduce Ceres’ biotech traits following positive results from greenhouse and field evaluations. Separately, the company announced that it has substantially increased plantings of its commercial forage sorghum hybrids in the U.S. over the prior year. Ceres, Inc. (NASDAQ:CERE) stock hit highest price at $1.98, beginning with a price of $1.98 to close at 1.81 by an advance of 0.56% with a day range of $1.80-$1.98. The total market capitalization remained 10.92 Million, total volume of 61340 shares held in the session was surprisingly higher than its average volume of 553.00 shares.